XML 46 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
BASIS OF FINANCIAL STATEMENT PRESENTATION (Details) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Accounts, Notes, Loans and Financing Receivable [Line Items]    
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification   $ 3.9
Weighted Average Number Diluted Shares Outstanding Adjustment   0.2
Ownership percentage below which investments are generally accounted for on the cost method (in thousandths) 20.00%  
Prior Period Reclassification Adjustment   $ 2.4
LabCorp Diagnostics [Member]    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Percent of Revenue Contributed 71.30%  
Covance Drug Development [Member]    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Percent of Revenue Contributed 28.70%